Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome

NCT01422486 is registered in ClinicalTrials.gov with Telik as lead sponsor.

NCT NCT01422486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01422486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Lead sponsor
Telik
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2011
Completion date
February 28, 2013
Enrollment
2 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome (mds)